Statistics from Altmetric.com
- bFGF, basic fibroblast growth factor
- ELISA, enzyme linked immunosorbent assay
- VEGF, vascular endothelial growth factor
Growth factors are currently emerging as a new therapeutic tool in coronary heart disease.1 Endogenous expression patterns of a number of angiogenic growth factors have been described in the chronically ischaemic and collateralised hearts.2 Through their proven experimental angiogenic effect, the administration of vascular endothelial growth factor (VEGF)3 and basic fibroblast growth factor (bFGF)1 have been explored as a means of increasing the degree of collateralisation in patients with end stage coronary heart disease. Questions remain however on the optimal dose, duration of administration, and monitoring of these agents1–3 as well as on the magnitude of risk posed by angiogenic cytokine treatment for accelerating atherosclerosis,4,5 partly because of the paucity of data on local growth factor concentrations and changes in living man. Patients with total coronary …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.